Annegret De Baey-Diepolder

Annegret de Baey-Diepolder is a Venture Partner at Seventure Partners SA, a leading international investor in the microbiome sector. Formerly she was co-founder and CEO of RNA-based immunotherapeutics company Rigontec GmbH, now Merck & Co., Inc.

As a life science industry consultant and former partner at private equity and venture capital companies TVM Capital and Gimv NV, she brings 20 years of experience in the life science and venture capital sector. Prior to joining the VC industry, she led a research group developing therapeutic vaccines at Micromet AG, now Amgen Inc.

Annegret de Baey-Diepolder is trained as an MD, and worked on her specialization in Dermatology and Allergology at academic hospital of the LMU in Munich. She received her postdoctoral training as a fellow of the German Research Foundation at the Basel Institute for Immunology.